Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma.
Loading...
Embargo End Date
Authors
Baker, LCJ
Sikka, A
Price, JM
Boult, JKR
Lepicard, EY
Box, G
Jamin, Y
Spinks, TJ
Kramer-Marek, G
Leach, MO
Eccles, SA
Box, C
Robinson, SP
Sikka, A
Price, JM
Boult, JKR
Lepicard, EY
Box, G
Jamin, Y
Spinks, TJ
Kramer-Marek, G
Leach, MO
Eccles, SA
Box, C
Robinson, SP
Document Type
Journal Article
Date
2018-07-23
Date Accepted
2018-07-02
Abstract
Background: Overexpression of EGFR is a negative prognostic factor in head and neck squamous cell carcinoma (HNSCC). Patients with HNSCC who respond to EGFR-targeted tyrosine kinase inhibitors (TKIs) eventually develop acquired resistance. Strategies to identify HNSCC patients likely to benefit from EGFR-targeted therapies, together with biomarkers of treatment response, would have clinical value. Methods: Functional MRI and 18F-FDG PET were used to visualize and quantify imaging biomarkers associated with drug response within size-matched EGFR TKI-resistant CAL 27 (CALR) and sensitive (CALS) HNSCC xenografts in vivo, and pathological correlates sought. Results: Intrinsic susceptibility, oxygen-enhanced and dynamic contrast-enhanced MRI revealed significantly slower baseline R2∗ , lower hyperoxia-induced ΔR2∗ and volume transfer constant Ktrans in the CALR tumors which were associated with significantly lower Hoechst 33342 uptake and greater pimonidazole-adduct formation. There was no difference in oxygen-induced ΔR1 or water diffusivity between the CALR and CALS xenografts. PET revealed significantly higher relative uptake of 18F-FDG in the CALR cohort, which was associated with significantly greater Glut-1 expression. Conclusions: CALR xenografts established from HNSCC cells resistant to EGFR TKIs are more hypoxic, poorly perfused and glycolytic than sensitive CALS tumors. MRI combined with PET can be used to non-invasively assess HNSCC response/resistance to EGFR inhibition.
Citation
Frontiers in oncology, 2018, 8 pp. 271 - ?
Source Title
Publisher
FRONTIERS MEDIA SA
ISSN
2234-943X
eISSN
2234-943X
Collections
Research Team
Magnetic Resonance
Preclinical Molecular Imaging
Pre-Clinical MRI
Radiotherapy Physics Modelling
Preclinical Molecular Imaging
Pre-Clinical MRI
Radiotherapy Physics Modelling